Prototypical molecular pharmacologic profile of lipophilic gabaergic a & b agonists against neurodegenerative and neurodevelopmental diseases
US2018193289A1
Prototypical molecular pharmacologic profile of fendiline against
neurodegenerative and neurodevelopmental diseases
US2017071879A1
Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline)
US2016367505A1
Prototypical analgesic profile of n-stearyl dopamine (ns-da)
US2015073046A1
Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
WO2013104933A1
3,3-diphenyl-n-(1-phenylethyl) propan-1 -amine : as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activity
EP2400965A1
Sigma( ) receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity
FR2897535A1
Sigma ligands: (mono- or di-alkylaminoalkyl) -y-butyrolactones, their aminotetrodrafuran analogues and (1-adamantyl) benzene (s) alkylamines as prototypic cellular receptor modulators
WO9730983A1
Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts
